Dr Chugh
Chen AP et al. Atezolizumab for advanced alveolar soft part sarcoma. N Engl J Med 2023;389(10):911-21. Abstract
D’Angelo SP et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): An international, open-label, phase 2 trial. Lancet 2024;403(10435):1460-71. Abstract
D’Angelo SP et al. Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): Interim analysis. ASCO 2021;Abstract 11521.
Gounder MM et al. Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma. Cancer 2021;127(8):1311-7. Abstract
Gounder M et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: An international, open-label, phase 2 basket study. Lancet Oncol 2020;21(11):1423-32. Abstract
Judson I et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trial. Lancet Oncol 2014;15(4):415-23. Abstract
Seddon B et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): A randomised controlled phase 3 trial. Lancet Oncol 2017;18(10):1397-110. Abstract
Wagner AJ et al. Phase II trial of nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (AMPECT): Long-term efficacy and safety update. J Clin Oncol 2024;42(13):1472-6. Abstract
Dr Gounder
Desmoid Tumor Working Group. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer 2020;127:96-107. Abstract
Gelderblom H et al. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2024;403(10445):2709-19. Abstract
Gounder M et al. Nirogacestat, a γ-secretase inhibitor for desmoid tumors. N Engl J Med 2023;388(10):898-912. Abstract
Kasper B et al. DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT). ESMO 2022;Abstract LBA2.
Niu X et al. MANEUVER: A phase III study of pimicotinib to assess efficacy and safety in tenosynovial giant cell tumor patients. Future Oncol 2024:1-8. Abstract
Penel N. TIKIN away: Expanding the role of tyrosine kinase inhibitors for the treatment of sarcomas. ASCO 2025;Oral Abstract Session.
Tap WD et al. The MOTION study: A randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor. Future Oncol 2024;20(10):593-601. Abstract
Tap WD et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): A randomised phase 3 trial. Lancet 2019;394(10197):478-87. Abstract